Non-Bovine Fibrin Sealant Launches In U.S.; Red Cross To Distribute Crosseal
This article was originally published in The Gray Sheet
Executive Summary
American Red Cross Plasma Services' three U.S. distributors will ship Omrix Biopharmaceuticals' Crosseal fibrin sealant to liver surgeons throughout the summer
You may also be interested in...
OPPS Data To Improve? Hospitals Join Device Groups In Supporting “C” Codes
The American Hospital Association and the Federation of American Hospitals are withdrawing opposition to "C" codes for device tracking, acknowledging potential quality improvements to data used to set payment rates under the hospital outpatient system
Ethicon seals Omrix deal
Wound management division of J&J unit gains exclusive North American marketing and distribution rights for Crosseal fibrin sealant from Belgian firm Omrix Biopharmaceuticals, adding to an exclusive European pact from June 2003. The first non-bovine sealant to launch in the U.S., Crosseal originally was cleared via biologics license application in March 2003 for use as an adjunct to hemostasis in liver surgery patients. Ethicon notes the device has a triple lumen delivery mechanism that does not mix the human thrombin and biological active component until they reach the tip - a feature that may prevent clogging seen in other sealants. Baxter's Tisseel uses aprotinin, a protein derived from cow lungs, and is Crosseal's chief competitor (1"The Gray Sheet" July 28, 2003, p. 16)...
OPPS Data To Improve? Hospitals Join Device Groups In Supporting “C” Codes
The American Hospital Association and the Federation of American Hospitals are withdrawing opposition to "C" codes for device tracking, acknowledging potential quality improvements to data used to set payment rates under the hospital outpatient system